Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 20/20 | 1.00 |
| ▸ | MMP13 | P45452 | 20/20 | 1.00 |
| ▸ | MMP2 | P08253 | 1/20 | 1.00 |
| ▸ | MMP3 | P08254 | 1/20 | 1.00 |
| ▸ | MMP9 | P14780 | 1/20 | 1.00 |
| ▸ | MMP8 | P22894 | 1/20 | 1.00 |
| ▸ | MMP12 | P39900 | 1/20 | 1.00 |
| ▸ | MMP14 | P50281 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7213054 | 0.93 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL25363 | 0.93 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL135680 | 0.93 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6962773 | 0.92 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6949842 | 0.89 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL15505961 | 0.89 | MMP1 (0.81) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6950243 | 0.89 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6964194 | 0.89 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6960491 | 0.89 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL14188830 | 0.88 | MMP1 (0.83) | MMP1MMP13MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 811 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070599-A1 | Crystal forms of 4-[4-(4-fluorophenoxy)benzenesulfonylamino]-tetrahydropyran-4-carboxylic acid hydroxyamide | EWING MARCUS DOUGLAS (US) | 2005-03-31 | — | — | US | claimed |
| WO-2004106319-A1 | CRYSTAL FORMS OF 4-[4-(4-FLUOROPHENOXY)BENZENESULFONYLAMINO]-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXYAMIDE | PFIZER PRODUCTS INC. (US) | 2004-12-09 | — | — | WO | claimed |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | PFIZER, INC. | 2003-03-06 | — | — | US | claimed |
| EP-1070058-A1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | Pfizer Products Inc. (US) | 2001-01-24 | — | — | EP | claimed |
| US-6087392-A | A METALLOPROTEINASE INHIBITORS FOR INHIBITING MAMMALIAN REPROLYSIN | PFIZER INC. (US) | 2000-07-11 | — | — | US | claimed |
| WO-1999052889-A1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PRODUCTS INC. (US) | 1999-10-21 | — | — | WO | claimed |
| EP-0930067-A2 | MMP INHIBITORS FOR THE TREATMENT OF OCULAR ANGIOGENESIS | Pfizer Products Inc. (US) | 1999-07-21 | — | — | EP | claimed |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-04-24 | — | — | US | disclosed |
| US-12037404-B2 | Human monoclonal antibodies against EphA4 and their use | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-07-16 | — | — | US | disclosed |
| EP-2534153-B2 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO}METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE | PFIZER (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2024-04-04 | — | — | US | disclosed |
| WO-2001034574-A1 | STABLE POLYMORPH OF N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-1070058-A1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | Pfizer Products Inc. (US) | 2001-01-24 | — | — | EP | disclosed |
| WO-2000047574-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| US-6087392-A | A METALLOPROTEINASE INHIBITORS FOR INHIBITING MAMMALIAN REPROLYSIN | PFIZER INC. (US) | 2000-07-11 | — | — | US | disclosed |
| WO-1999052889-A1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PRODUCTS INC. (US) | 1999-10-21 | — | — | WO | disclosed |
| EP-0949244-A2 | Process for preparing hydroxamic acids | Pfizer Products Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0930067-A2 | MMP INHIBITORS FOR THE TREATMENT OF OCULAR ANGIOGENESIS | Pfizer Products Inc. (US) | 1999-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | MMP1 3955/4885MMP13 4604/4885MMP2 4086/4885 |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | MMP1 2061/4885MMP13 4280/4885MMP2 3813/4885 |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | GRIN3A, GRIN1, CHRNA10 | MMP1 326/4885MMP13 272/4885MMP2 231/4885 |
| US-20050070599-A1 | Crystal forms of 4-[4-(4-fluorophenoxy)benzenesulfonylamino]-tetrahydropyran-4-carboxylic acid hydroxyamide | HCAR2, HCAR3, HCAR1 | MMP1 4148/4885MMP13 2541/4885MMP2 2344/4885 |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | MMP1 3955/4885MMP13 4604/4885MMP2 4086/4885 |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | MMP1 2061/4885MMP13 4280/4885MMP2 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.